SC
ALNY icon

SummitTX Capital’s Alnylam Pharmaceuticals ALNY Stock Holding History

SummitTX Capital’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$703K Sell
2,336
-1,275
-35% -$385K 0.02% 529
2026
Q1 		$1.19M Buy
3,611
+146
+4% +$49.7K 0.04% 404
2025
Q4 		$1.38M Sell
3,465
-4,060
-54% -$1.8M 0.04% 360
2025
Q3 		$3.43M Buy
7,525
+2,725
+57% +$1.11M 0.14% 165
2025
Q2 		$1.57M Sell
4,800
-1,526
-24% -$422K 0.07% 288
2025
Q1 		$1.71M Buy
+6,326
New +$1.63M 0.07% 278

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

SummitTX Capital's ALNY Position: Q2 2026 in Review

SummitTX Capital reduced its Alnylam Pharmaceuticals (ALNY) stake by 35% in Q2 2026, selling an estimated $385K and leaving 2,336 shares worth $703K. The position accounts for 0.02% of the portfolio, ranked #529.

SummitTX Capital first reported a position in ALNY in Q1 2025 and has held it in 6 quarters since. The position peaked at $3.43M in Q3 2025. 788 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • SummitTX Capital held 2,336 shares of Alnylam Pharmaceuticals worth $703K as of Q2 2026.
  • SummitTX Capital sold 1,275 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $385K.
  • Alnylam Pharmaceuticals made up 0.02% of SummitTX Capital's portfolio in Q2 2026, its #529 holding.
  • SummitTX Capital first reported a position in Alnylam Pharmaceuticals in Q1 2025 and has held it in 6 quarters since.
  • SummitTX Capital's Alnylam Pharmaceuticals position peaked at $3.43M in Q3 2025.
  • 788 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on SummitTX Capital's 13F filing for Q2 2026, filed 14 Aug 2026.